Check for updates

OPEN ACCESS

EDITED BY Ivana Šarac, University of Belgrade, Serbia

REVIEWED BY Rizaldy Taslim Pinzon, Duta Wacana Christian University, Indonesia Jenq-Shyong Chan, Taoyuan Armed Forces General Hospital, Taiwan

*CORRESPONDENCE Hui-Bin Huang ⊠ psyc6789@163.com

[†]These authors have contributed equally to this work

RECEIVED 03 October 2024 ACCEPTED 07 April 2025 PUBLISHED 30 April 2025

CITATION

Zheng W-H, Shi J-H, Yu D-X and Huang H-B (2025) Vitamin D supplementation in critically ill patients: a meta-analysis. *Front. Nutr.* 12:1505616. doi: 10.3389/fnut.2025.1505616

COPYRIGHT

© 2025 Zheng, Shi, Yu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Vitamin D supplementation in critically ill patients: a meta-analysis

Wen-He Zheng^{1†}, Jia-Heng Shi^{2†}, Da-Xing Yu² and Hui-Bin Huang^{2*}

¹Department of Critical Care Medicine, The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, China, ²Department of Critical Care Medicine, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Background: Vitamin D is commonly used in clinical practice, while its clinical significance in critically ill patients remains controversial. Therefore, we aimed to perform a systemic review and meta-analysis to investigate the effect of vitamin D on this patient population.

Methods: We searched for randomized controlled trials (RCTs) in PubMed, Embase, and the Cochrane Library databases from inception until August 15, 2024. Studies evaluating critically ill adult patients who received vitamin D compared to controls were included. The primary outcome was short-term mortality. We used the Cochrane risk of bias tool and GRADE system to evaluate the study quality and evidence. Secondary outcomes were changes in serum 25-hydroxyvitamin D levels, mechanical ventilation (MV) duration, and length of stay (LOS) in the ICU or hospital. We also conducted meta-regression, subgroup analyses, and trial sequential analysis (TSA) to explore the potential heterogeneity among the included trials.

Results: Nineteen RCTs with 2,754 patients were eligible. Overall, vitamin D significantly increased serum 25-hydroxyvitamin D levels and significantly reduced the short-term mortality (risk ratio [RR] = 0.83; 95%Cl, 0.70–0.98; p = 0.03, $l^2 = 13\%$), duration of MV (MD = -2.96 days; 95% Cl, -5.39 to -0.52; $l^2 = 77\%$; p = 0.02) and ICU LOS (MD = -2.66 days; 95% Cl, -4.04 to -1.29, $l^2 = 70\%$; p = 0.0001) but not hospital LOS (MD = -0.48 days; 95% Cl, -2.37 to 1.40; $l^2 = 31\%$; p = 0.61). The meta-regression analysis revealed that the proportion of MV (MV%) accounted for the source of heterogeneity, and the subgroup analyses based on MV% suggested that the MV group was more likely to benefit from vitamin D applications than the partly MV group in all the predefined outcomes (all *p* values<0.05). TSA for short-term mortality suggested that more data is required to confirm our main conclusion.

Conclusion: Vitamin D supplementation increased serum 25-hydroxyvitamin D levels and significantly benefited critically ill patients, especially those with MV.

Systematic review registration: https://inplasy.com/inplasy-2022-10-0074/, INPLASY2022100074.

KEYWORDS

vitamin D, critical illness, mechanical ventilation, meta-analysis, mortality

Introduction

Vitamin D is a fat-soluble vitamin that regulates calciumphosphorus levels in bone metabolism (1), as well as various body processes, including hormonal regulation, immunomodulatory, oxidative stress, cardiovascular, and muscular effects (2, 3). To achieve its bioactive hormone state, vitamin D must be hydroxylated in the liver and kidneys to form 25-hydroxyvitamin D (25-OHD) and 1,25-OHD (1). Previously published studies used a targeted value of 30 ng/mL 25-OHD levels to define vitamin D deficiency (VDD) according to the suggestion of Endocrine Society clinical practice guideline (4). However, in 2024, the up-dated guideline abandoned these recommendations because they did not find enough scientific confirmation (5). In contrast, the Institute of Medicine and European Food Safety Authority recommended 20 ng/mL (50 nmol/L) which has not changed (6, 7). In addition, other associations such as the International Osteoporosis Foundation and the American Geriatrics Society also use 30 ng/mL as a guideline goal (8, 9).

Nevertheless, VDD is common in critically ill patients (10). It is associated with severe complications (i.e., infection, acute liver failure, acute respiratory insufficiency), development of sepsis, prolonged mechanical ventilation (MV), and mortality (10, 11). In contrast, vitamin D supplementation has been shown to significantly improve the prognosis in mechanically ventilated patients (12). Therefore, vitamin D supplementation in critically ill patients may be essential and is recommended by some guidelines of clinical nutrition (13).

However, two large RCTs failed to show the prognostic value of vitamin D for critically ill patients (14, 15). Meta-analyses have produced conflicting results in recent years. Previous meta-analyses either included a limited number of trials or were contaminated with observational studies. This has led to non-robust results. Of note, three recently published meta-analyses reached inconsistent conclusions (16–18). Two of them did not support the survival benefits of vitamin D in critically ill patients (16, 18), but the third, published by Menger and colleagues, showed that vitamin D reduces mortality in this patient population (17). Some of these meta-analyses, which further explored factors like the route or dose of vitamin D administration, could not resolve the heterogeneity of their main results (16–18).

Interestingly, all of the authors' perspectives were based on the assumption that supplemental vitamin D was associated with its increased concentration *in vivo* (16–18). However, they failed to provide relevant data for analyzing vitamin D concentrations. Furthermore, all three meta-analyses suggest that vitamin D significantly reduces the duration of MV, which is questionable (16–18). It also remains unclear whether the selected patient populations affected the results.

Considering the highly heterogeneous group of critically ill patients and variations in study design and implementation among the included studies, clarifying the optimal regimen for vitamin D is essential. Therefore, with the power of meta-analysis techniques, we aimed to include newly published RCTs to evaluate the effect of vitamin D on mortality and other important clinical outcomes in critically ill patients. We also explored the influences of vitamin D-associated factors with the help of meta-regression analysis and subgroup analyses.

Method

The present study's protocol has been registered on the International Platform of Registered Systematic Review and Metaanalysis Protocols database (Registration number: INPLASY2022100074). We conducted our study and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (19) (Supplementary file 1).

Eligibility criteria

Predefined criteria for eligible studies were as follows:

- 1. The studies should include critically ill adult patients;
- 2. The intervention group received vitamin D regardless of any regimen (i.e., dose, timing, and route administration);
- 3. The control group received a placebo or no drug or usual care;
- 4. The primary outcome was short-term mortality [defined as ICU or hospital or 28-day mortality, or mortality within 90 days after discharge from the hospital, the longest period was preferred (20)]. Secondary outcomes were serum changes between groups after the intervention, the length of stay (LOS) in the ICU or hospital, and the duration of MV;
- 5. RCTs.

We excluded studies conducted in pregnant women, reviews, case reports, case series, *post hoc* analyses, or studies that did not report any predefined outcomes.

Search strategy

Two authors (W-HZ and J-HS) independently searched for eligible studies in the PubMed, Embase, and Cochrane Library databases before October 15, 2022, which was the last search. Details of the search strategy are summarized in Supplementary file 2. No language limitation was imposed. Grey literature¹ was also searched. We also evaluated the reference lists of relevant studies and previous meta-analyses to ensure the inclusion of all potential studies. Discrepancies were identified and resolved by a third author (H-BH) with arbitration.

Data extraction

The two authors (W-HZ and J-HS) extracted the data independently on the first author's name, publication year, sample size, inclusion criteria, patient characteristics (age, gender, and disease severity), study quality, Vitamin D regimens, as well as predefined

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; ICU, intensive care unit; IM, intramuscular; IQR, interquartile range; IV, intravenous; MD, mean difference; MV, mechanical ventilation; RR, risk ratio; RCTs, randomized controlled trials; SD, standard deviations; TSA, trial sequential analysis; VDD, vitamin D deficiency.

¹ https://www.basesearch.net; https://scholar.google.com

outcomes. Discrepancies were resolved by discussion. Authors of the included RCTs were contacted for missing or unclear information of primary outcomes if required.

Quality assessment

The Cochrane risk of bias tool was used to assess the methodological quality of the individual RCTs (21). For each included trial, we assigned a risk of bias rating of "low," "unclear," or "high" for the following items: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other biases. An individual trial's overall risk of bias was classified as "low" (if the risk of bias was low in all domains), "moderate" (if the risk of bias was unclear in at least one domain, with no high risk of bias domains), or "high" (if the risk of bias was high in at least one domain). We also used the GRADE system to evaluate the quality of evidence. Disagreements were settled by discussion and consensus. When at least 10 trials were included in our meta-analysis, we evaluated publication bias by visually analyzing funnel plots and using Egger's test.

Statistical analysis

The results from all relevant studies were combined to estimate the pooled risk ratio (RR) and associated 95% confidence intervals (CI) for dichotomous outcomes. As to the continuous outcomes, we estimated mean differences (MD) and 95% CI as effective results. For studies that reported a median with an accompanying interquartile range (IQR) or range as the measure of treatment effect, we estimated the mean from the median and standard deviations (SD) from the IQR or range using the methods described in the previous studies before data analysis (22, 23). We used the I^2 statistic to test the heterogeneity. An $I^2 < 50\%$ was considered insignificant heterogeneity, and an $I^2 > 50\%$ was regarded as substantial heterogeneity (24). We performed trial sequential analysis (TSA) for short-term mortality with the random-effect (DL) model to adjust the significance levels for sparse data and repetitive testing on accumulating data in the current meta-analysis (25). Thus, we defined the required information size for decreased mortality based on a risk of type I error of 5%, a risk of type 2 error of 20%, the control group outcome, and a relative risk reduction of 24.8 and 20% to calculate the required information size and the cumulative Z-curve's eventual breach of relevant trial sequential monitoring boundaries. We performed all analyses using Review Manager, Version 5.3, TSA Viewer Version 0.9, and STATA Version 13.0 (College Station, TX, United States).

To test the robustness of the outcomes and explore the potential influence factors, we conducted sensitivity analyses to investigate the influence of a single study on the overall pooled estimate of each predefined outcome. We performed meta-regression based on several vitamin D-related clinical variables, including the proportion of patients with MV (MV%) (100% vs. mixed), vitamin D dose (\leq 300,000 UI vs. >300,000 UI), serum vitamin D level at baseline (VDD, defined as <20 ng/mL vs. <30 ng/mL vs. no threshold), design (single center vs. multicenter study), and route of vitamin D administration (enteral/oral vs. intravenous/intramuscular injection, IV/IM) to explore the possible source of heterogeneity among the included trials. Then the subgroup analyses were conducted according to the results of the meta-regression.

Results

Search results

The electronic search retrieved 720 citations, 474 of which were selected from the de-duplicated results. After independently screening the titles and abstracts, we identified 31 relevant articles in full text for eligibility. Finally, 19 RCTs with 2,754 patients were included in the final analysis (14, 15, 26–42). Figure 1 shows a flowchart for selecting studies, and the studies needed for full review but not included in the current meta-analysis are summarized in Supplementary file 3.

Studies characteristics

The main characteristics of the included studies are listed in Table 1. Eligible studies were published between 2011 and 2021 and were conducted in nine countries. 13 RCTs were conducted in multicenters, while six were single-center studies (14, 15, 28, 33, 34, 36). All but one study (35) used the double-blinded design. Among the included trials, 12 focused on only patients with MV (27–29, 32–36, 38–42), and 10 provided clear VDD definition (defined as serum vitamin D < 20 ng/mL) (Supplementary file 4). Most of the included studies reported the details of the vitamin D regimen. Regarding the route of vitamin D administration, 11 RCTs used enteral/oral (14, 15, 26–28, 31, 35–39, 42), seven RCTs used IM/IV (30, 32–34, 39–41), while the remaining one evaluated both ways of vitamin D administration compared to usual care (29).

Risk of bias in studies

Six RCTs were considered at low risk of bias (14, 15, 26, 27, 37, 41), 10 were judged to be at moderate risk of bias (28–34, 36, 38, 42), and three trials were deemed at high risk of bias (35, 39, 41) (Supplementary file 5). Using GRADE methodology, we evaluated the evidence for short-term mortality and duration of MV to be low, whereas ICU LOS, hospital LOS, and changes in 25(OH)D concentrations were very low (Supplementary file 6). Assessment of publication bias using visually inspecting funnel plots showed no skewed distributions, suggesting no potential publication bias among the included trials (Supplementary file 7). We further investigated publication bias by conducting Egger tests; there was also no evidence of publication bias (Kendall's tau = 0.0588, p = 0.7652).

Serum 25-hydroxyvitamin D level

A total of 15 RCTs reported the serum 25(OH)D concentrations at baseline and after intervention (most at 3–7 days later, provided by each trial) (Supplementary file 8). Among them, 14 provided specific data that could be pooled (14, 15, 26–29, 31, 33, 36–39, 42). Overall, the changes in plasma 25(OH)D concentrations after intervention in the vitamin D group were more significant than in the control group (n = 1,519; MD = 12.89 ng/mL; 95% CI, 8.17 to 17.61; $I^2 = 96\%$; p < 0.00001). Similar results were also observed when only trials of vitamin D administered by enteral/oral (p < 0.00001), trials of vitamin D dose



(p < 0.00001), trials of low vitamin D dose (p < 0.00001), or Vit D administration in partly/100% MV cohort (p < 0.00001), were pooled, respectively. Details of results were summarized in Table 2.

In addition, vitamin D administered by enteral/oral resulted more increased serum 25(OH)D concentrations than that by IV/IM (17.16 ng/mL vs. 5.72 ng/mL), while the high vitamin D dose administered had more increased serum concentrations than the low vitamin D dose (18.96 ng/mL vs. 9.96 ng/mL). However, the direct comparisons were unsuitable because of pooled results from different studies (Supplementary file 9).

Primary outcome

All 19 RCTs reported the outcome of short-term mortality. The pooled analysis showed that compared with the control group, vitamin D supplementation significantly reduced the risk of mortality (n = 2,664, RR = 0.83; 95% CI, 0.70 to 0.98; $I^2 = 13\%$; p = 0.03) (Figure 2) in critically ill patients. We proceeded to perform meta-regression analyses across predefined potential clinical factors. The results suggest that only MV% (p = 0.039) rather than vitamin D dose (p = 0.171), serum 25(OH)D level at baseline (0.134), single center or multicenter study design (0.958), and route of vitamin D delivery (p = 0.083) was the potential

source of heterogeneity among the included trials (Supplementary file 10). Subsequently, we conducted subgroup analysis based on MV% and found that vitamin D significantly reduced the short-term mortality in the MV subgroup (0.65 [0.50, 0.84]; p = 0.0009) in comparison to that in the partial MV subgroup (0.98 [0.84, 1.15], p = 0.80), with no heterogeneity shown in both two subgroup findings ($I^2 = 0\%$) (Figure 2).

TSA for the results of short-term mortality was provided in Supplementary file 11. The cumulative z-curve crossed the conventional boundary (Z-statistic above 1.96) for benefit but did not cross the trial sequential monitoring boundary for benefit. Meanwhile, the number of patients included in TSA did not exceed the required information size of 5,001.

Secondary outcomes

Compared with the control group, vitamin D supplementation significantly decreased the duration of MV (11 RCTs, n = 1,016, MD = -2.96 days; 95% CI, -5.39 to -0.52; I^2 = 77%; p = 0.02) (Figure 3) (14, 15, 26–30, 33, 38, 41, 42) and the ICU LOS (17 RCTs, n = 2,322, MD = -2.66 days, 95% CI, -4.04 to -1.29, I^2 = 70%, p = 0.0001) (Figure 4) (14, 15, 26–33, 35–39, 41, 42). Nine RCTs provided specific data on the outcome of hospital LOS and pooled

TABLE 1 Characteristics of the included studies.

Study	Country	Design	N	Age	VDD	MV%	Route	Vitamin D dose	ROB
Amrein 2011 (26)	Austria	SC, DB	25	61/64	100%	84%	Enteral	Single dose of 540,000 IU	L
Amrein 2014 (14)	Austria	MC, DB	492	64/65	100%	64%	Enteral	Loading dose of 540,000 IU; then 90,000 IU/month x 5	L
Leaf 2014 (32)	USA	SC, DB	67	68/58	Unlimited	70%	IV	Calcitriol 2 mcg	U
Ginde 2019 (15)	USA	MC, DB	1,078	57/55	100%	33%	Enteral	Single dose of 540,000 IU	L
Karsy 2019 (31)	USA	SC, DB	267	58/56	100%	Mixed	Enteral	Single dose of 540,000 IU	U
Quraishi 2015 (37)	USA	SC, DB	30	63/65	Unlimited	Mixed	Enteral	Single dose of 200,000 IU or 400,000 IU	L
Sharma 2021 (38)	India	SC, DB	35	36	100%	100%	Enteral	Single dose of 120,000 IU	U
Bhattacharyya 2021 (27)	India	SC, DB	126	42/44	100%	100%	Enteral	Single dose of 540,000 IU	L
Miroliaee 2017 (34)	Iran	MC, DB	46	67/59	100%	100%	IM	Single dose of 300,000 IU	U
Ding 2017 (41)	China	SC, DB	57	29/28	100%	100%	IM	Single dose of 300,000 IU	L
Miri 2019 (33)	Iran	MC, DB	40	64/72	100%	100%	IM	Single dose of 300,000 IU	U
Han 2016 (28)	USA	MC, DB	31	67/65	Unlimited	100%	Enteral	50,000 IU/day × 5 or 100,000 IU/day × 5	U
Hasanloei 2019 (29)	Iran	SC, DB	72	47/49	100%	100%	Enteral/IM	Single dose of 500,000 IU or 300,000 IU	U
Parekh 2018 (36)	UK	MC, DB	79	65/66	100%	100%	Enteral	Single dose of 300,000 IU	U
Sistanizad 2021 (39)	Iran	SC, DB	36	62/58	100%	100%	IM	Single dose of 300,000 IU	Н
Yousefian 2019 (40)	Iran	SC, DB	99	70/67	100%	100%	IM	300,000 IU up to three doses per week	Н
Naguib 2020 (35)	Egypt	SC, UB	89	44/43	Unlimited	100%	Enteral	Alfacalcidol 2 mg/d started two days before surgery	Н
Ingels 2020 (30)	Belgium	SC, DB	24	58/52	100%	100%	IV	Loading 200 µg calcidiol; 15 µg/day × 10	U
Wang 2024 (42)	China	MC, DB	61	71/65	100%	83.6%	Enteral	Single dose of 75,000 IU \times 8	U

DB, double blind; H, high risk; IM, intramuscular; IV, intravenous; L, low risk; MC, multi-centers; Mixed, only part patients received mechanical ventilation; ROB, risk of bias; SC, single center; U, unclear risk; VDD, vitamin D deficiency (defined as <30 ng/mL); UB, unblind.

Subgroup	Included studies	N	Effect estimate; MD (95%CI)	l ²	P value
All of the included studies	(14, 15, 26-31, 33, 36-39, 42)	1,519	12.89 [8.17, 17.61]	96	<0.00001
Vit D dose >300,000	(14, 15, 26-29, 31, 37, 42)	1,314	16.19 [9.65, 22.73]	97	< 0.00001
Vit D Dose ≤300,000	(28–30, 33, 36–39)	272	8.73 [4.92, 12.55]	85	< 0.00001
Vit D administration by IV/IM	(29, 33, 39)	142	6.57 [2.00, 11.14]	91	0.005
Vit D administration by EN/oral	(14, 15, 26-31, 36-38, 42)	1,449	14.49 [9.16, 19.81]	96	< 0.00001
Vit D administration in partly MV	(27-30, 33, 36, 38, 39, 42)	459	8.28 [4.73, 11.84]	86	<0.00001
cohort					
Vit D administration in 100% MV	(14, 15, 26, 31, 37)	1,060	19.15 [7.72, 30.59]	98	0.001
cohort					

TABLE 2 Comparison of the changes in serum 25-hydroxyvitamin levels between vitamin D and control in subgroup critically ill patients.

CI, confidence interval; N, enteral; IM, intramuscular; IV, intravenous; MD, mean difference; Vit D, vitamin D.

Study on Subanaun	Maan	00	Total	Meen	00	Tatal	Mainht	IV Bandam 05% Cl	IV Bandom 05% Cl
Study or Subgroup	wean	50	Total	wean	50	Total	weight	IV, Random, 95% CI	IV, Random, 95% CI
Amrein 2011	6.8	8.8	10	9.5	13.5	11	4.5%	-2.70 [-12.36, 6.96]	
Amrein 2014	6.9	13.2	159	6.9	17.3	161	12.0%	0.00 [-3.37, 3.37]	
Bhattacharyya 2021	5	6.3	63	7	17	63	10.2%	-2.00 [-6.48, 2.48]	
Ding 2017	1.7	2.3	29	2.8	3.8	28	14.6%	-1.10 [-2.74, 0.54]	
Ginde 2019	6.7	11.3	119	5.9	10.5	121	13.0%	0.80 [-1.96, 3.56]	-
Han 2016	13	10	20	20	15	10	4.1%	-7.00 [-17.28, 3.28]	
Hasanloei 2019	20	9.7	48	31	4.9	24	12.0%	-11.00 [-14.37, -7.63]	
Ingels 2020	13	5.6	11	19.3	11.2	13	6.9%	-6.30 [-13.23, 0.63]	
Miri 2019	17.6	14	22	27.7	22.5	18	3.3%	-10.10 [-22.03, 1.83]	
Sharma 2021	4.7	2.2	20	8.2	2.7	15	14.6%	-3.50 [-5.17, -1.83]	
Wang 2024	24	19.3	35	17	14.6	16	4.6%	7.00 [-2.59, 16.59]	
Total (95% CI)			536			480	100.0%	-2.96 [-5.39, -0.52]	•
Heterogeneity: Tau ² =	9.87: Ch	$hi^2 = 43$	3.45. df	= 10 (F	< 0.0	0001):	$^{2} = 77\%$	1979) III II II	

FIGURE 2

Forest plots of the effect of vitamin D supplementation on short-term mortality. Partly MV = only part of patients received mechanical ventilation. 100% MV = all patients received mechanical ventilation.

	Vit	amin I	D	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.3.1 Partly MV									
Amrein 2011	16	17.8	12	15	22.2	13	1.4%	1.00 [-14.72, 16.72]	
Amrein 2014	20.1	30.1	237	19.3	25.7	238	10.7%	0.80 [-4.23, 5.83]	- - -
Karsy 2019	10.4	14.5	134	9.1	7.9	133	22.5%	1.30 [-1.50, 4.10]	
Leaf 2014	22	11.1	36	21	11.1	31	9.8%	1.00 [-4.33, 6.33]	
Quraishi 2015	14.5	7.8	20	37	30	10	1.0%	-22.50 [-41.41, -3.59]	
Subtotal (95% CI)			439			425	45.3%	0.41 [-2.87, 3.68]	•
Heterogeneity: Tau ² =	4.34; Ch	ni² = 5.	96, df =	= 4 (P =	0.20);	l ² = 33	%		
Test for overall effect:	Z = 0.24	(P = (0.81)						
1.3.2 100% MV									
Bhattacharyya 2021	12	39	63	12	51	63	1.4%	0.00 [-15.85, 15.85]	
Han 2016	25	14	20	36	19	10	1.9%	-11.00 [-24.28, 2.28]	
Naguib 2020	8	2.2	45	9.5	3.9	41	36.1%	-1.50 [-2.86, -0.14]	-
Parekh 2018	13	8.9	33	13	7.4	35	15.3%	0.00 [-3.90, 3.90]	
Subtotal (95% CI)			161			149	54.7%	-1.42 [-2.69, -0.15]	•
Heterogeneity: Tau ² =	0.00; Cł	ni² = 2.	55, df =	= 3 (P =	0.47);	$ ^2 = 0\%$	b		
Test for overall effect:	Z = 2.19	(P = (0.03)						
Total (95% CI)			600			574	100.0%	-0.48 [-2.37, 1.40]	•
Heterogeneity: Tau ² =	2.09; Ch	ni² = 1'	1.55. df	= 8 (P =	= 0.17); $ ^2 = 3$	1%	_	
		-		. (·		100 E			-20 -10 0 10 20

FIGURE 3

Forest plots of the effects of vitamin D supplementation on the duration of mechanical ventilation.

Study or Subgroup Me I.2.1 Partly MV Amrein 2011 Amrein 2014 Sinde 2019 Ginde 2019 Leaf 2014 Quraishi 2015 Wang 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Hasanloei 2019 Yarekh 2018 Sharma 2021 Sistanizad 2021 Gistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	22an 10 9.6 9.1 6.4 8 3 11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	SD 7.96 13.2 9.2 9.8 9.6 7 8.9 j² = 19. (P = 0. 22 4.1 11.7 16.7 8.9	Total 12 237 406 134 36 20 41 886 .46, df .08) 63 29 20 48 11	Mean 6 10.7 10.4 5.4 12 12.5 = 6 (P = 9 6.7 23 49.3 23	SD 14.23 17.3 11 6.4 7.4 6 7.41 = 0.003; 52 4.9 14 6.6	Total 13 238 418 133 31 10 20 863); I² = 6! 63 28 15 24	Weight 2.0% 8.3% 11.0% 9.9% 5.9% 4.9% 5.7% 47.7% 9% 0.9% 0.9% 9.1% 2.1% 4.2%	IV. Random, 95% Cl 4.00 [-4.95, 12.95] -1.10 [-3.87, 1.67] -1.30 [-2.68, 0.08] 1.00 [-0.98, 2.98] -5.00 [-9.08, -0.92] -9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	IV. Random. 95% Cl
I.2.1 Partly MV Amrein 2011 Amrein 2014 Amrein 2014 Sinde 2019 Ginde 2019 eaf 2014 Quraishi 2015 Wang 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 11 Jana 2016 12 Parekh 2019 Sharma 2020 Viri 2019 Parekh 2018 Sharma 2021 Sistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	10 9.6 9.1 6.4 8 3 11 2; Ch 1.75 5.5 5.9 5.3 18 9.5	7.96 13.2 9.2 9.8 9.6 7 8.9 $i^2 = 19.$ (P = 0. 22 4.1 11.7 16.7 8.9	12 237 406 134 36 20 41 886 .46, df .08) 63 29 20 48 11	6 10.7 10.4 5.4 12 12.5 = 6 (P = 9 6.7 23 49.3	14.23 17.3 11 6.4 7.4 6 7.41 = 0.003; 52 4.9 14 6.6	13 238 418 133 31 10 20 863); ² = 6 3 63 28 5 24	2.0% 8.3% 11.0% 9.9% 4.9% 5.7% 47.7% 9%	4.00 [-4.95, 12.95] -1.10 [-3.87, 1.67] -1.30 [-2.68, 0.08] 1.00 [-0.98, 2.98] -5.00 [-9.08, -0.92] -9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Amrein 2011 Amrein 2014 9 Sinde 2019 9 Sinde 2019 9 Karsy 2019 9 eaf 2014 2 Quraishi 2015 Nang 2024 Subtotal (95% CI) 9 Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% 3 Bhattacharyya 2021 0 Ding 2017 9 Han 2016 11 Hasanloei 2019 3 ngels 2020 9 Viri 2019 19 Parekh 2018 5 Sharma 2021 0 Sistanizad 2021 11 Subtotal (95% CI) 14 Heterogeneity: Tau ² = 5.97 7 Fest for overall effect: Z = 3 10	10 9.6 9.1 6.4 8 3 11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	7.96 13.2 9.2 9.8 9.6 7 8.9 i ² = 19. (P = 0. 22 4.1 11.7 16.7 8.9	12 237 406 134 36 20 41 886 .46, df .08) 63 29 20 48 11	6 10.7 10.4 5.4 12 12.5 = 6 (P = 9 6.7 23 49.3	14.23 17.3 11 6.4 7.4 6 7.41 = 0.003) 52 4.9 14 6.6	13 238 418 133 31 10 20 863); ² = 6 63 28 15 24	2.0% 8.3% 11.0% 9.9% 5.9% 4.9% 5.7% 47.7% 9%	4.00 [-4.95, 12.95] -1.10 [-3.87, 1.67] -1.30 [-2.68, 0.08] 1.00 [-0.98, 2.98] -5.00 [-9.08, -0.92] -9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Amrein 2014 Sinde 2019 Sinde 2019 Sinde 2019 Sinde 2014 Leaf 2014 Quraishi 2015 Nang 2024 Subtotal (95% CI) Subtotal (95% CI) Heterogeneity: Tau² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Shattacharyya 2021 Subtotal (95% CI) Ding 2017 Sistanloei 2019 Sistanloei 2019 Vaguib 2020 Sistanizad 2021 Sistanizad 2021 Parekh 2018 Sharma 2021 Sistanizad 2021 Subtotal (95% CI) Heterogeneity: Tau² = 5.97 Fest for overall effect: Z = 3	9.6 9.1 6.4 8 3 11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	13.2 9.2 9.8 9.6 7 8.9 $i^2 = 19.$ (P = 0. 22 4.1 11.7 16.7 8.9	237 406 134 36 20 41 886 .46, df .08) 63 29 20 48 11	10.7 10.4 5.4 13 12 12.5 = 6 (P = 9 6.7 23 49.3 23	17.3 11 6.4 7.4 6 7.41 = 0.003) 52 4.9 14 6.6	238 418 133 31 10 20 863); ² = 6 63 28 15 24	8.3% 11.0% 9.9% 5.9% 4.9% 5.7% 47.7% 9%	-1.10 [-3.87, 1.67] -1.30 [-2.68, 0.08] 1.00 [-0.98, 2.98] -5.00 [-9.08, -0.92] -9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Sinde 2019 Sinde 2019 Sinde 2014 Quraishi 2015 Wang 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Hasanloei 2019 Yaarablei 2019 Viri 2019 Viri 2019 Parekh 2018 Sharma 2021 Sistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	9.1 6.4 8 3 11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	9.2 9.8 9.6 7 8.9 i ² = 19. (P = 0. 22 4.1 11.7 16.7 8.9	406 134 36 20 41 886 .46, df .08) 63 29 20 48 11	10.4 5.4 13 12 12.5 = 6 (P = 9 6.7 23 49.3 23	11 6.4 7.4 6 7.41 = 0.003; 52 4.9 14 6.6	418 133 31 10 20 863); ² = 6 63 28 15 24	11.0% 9.9% 5.9% 4.9% 5.7% 47.7% 9%	-1.30 [-2.68, 0.08] 1.00 [-0.98, 2.98] -5.00 [-9.08, -0.92] -9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Karsy 2019 .eaf 2014 Leaf 2014	6.4 8 3 11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	9.8 9.6 7 8.9 j ² = 19. (P = 0. 22 4.1 11.7 16.7 8.9	134 36 20 41 886 .46, df .08) 63 29 20 48 11	5.4 13 12 12.5 = 6 (P = 9 6.7 23 49.3 23	6.4 7.4 6 7.41 = 0.003; 52 4.9 14 6.6	133 31 10 20 863); ² = 6 63 28 15 24	9.9% 5.9% 4.9% 5.7% 47.7% 9% 0.9% 0.9% 9.1% 2.1%	1.00 [-0.98, 2.98] -5.00 [-9.08, -0.92] -9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Leaf 2014 Quraishi 2015 Nang 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 9 Han 2016 19 Hasanloei 2019 39 ngels 2020 Viiri 2019 19 Naguib 2020 20 Parekh 2018 Sharma 2021 0 Sistanizad 2021 14 Subtotal (95% CI) Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	8 3 11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	9.6 7 8.9 $i^2 = 19.$ (P = 0. 22 4.1 11.7 16.7 8.9	36 20 41 886 .46, df .08) 63 29 20 48 11	13 12 12.5 = 6 (P = 9 6.7 23 49.3 23	7.4 6 7.41 = 0.003) 52 4.9 14 6.6	31 10 20 863); ² = 6 63 28 15 24	5.9% 4.9% 5.7% 47.7% 9% 0.9% 0.9% 9.1% 2.1%	-5.00 [-9.08, -0.92] -9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	• •
Quraishi 2015 Wang 2024 Subtotal (95% CI) Heterogeneity: Tau² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 1.1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 1.1.2.2 100 MV% Bhattacharyya 2021 Uing 2017 Han 2016 1.1.2.2 100 MV% Bhattacharyya 2021 Viri 2019 Yaguib 2020 Parekh 2018 Sharma 2021 Shatmizad 2021 Visubtotal (95% CI) Heterogeneity: Tau² = 5.97 Fest for overall effect: Z = 3	3 11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	7 8.9 i ² = 19. (P = 0. 22 4.1 11.7 16.7 8.9	20 41 886 .46, df .08) 63 29 20 48 11	12 12.5 = 6 (P = 9 6.7 23 49.3 23	6 7.41 = 0.003) 52 4.9 14 6.6	10 20 863); I ² = 6 63 28 15 24	4.9% 5.7% 47.7% 9% 0.9% 0.9% 9.1% 2.1%	-9.00 [-13.82, -4.18] -1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	• •
Wang 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 1.4.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 1.1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 1.1.2.2 100 MV% Bhattacharyya 2021 Viri 2019 Yaguib 2020 Parekh 2018 Sharma 2021 Sistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	11 2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	8.9 i ² = 19. (P = 0. 22 4.1 11.7 16.7 8.9 12.2	41 886 .46, df .08) 63 29 20 48 11	12.5 = 6 (P = 9 6.7 23 49.3 23	7.41 = 0.003) 52 4.9 14 6.6	20 863); ² = 6 63 28 15 24	5.7% 47.7% 9% 0.9% 9.1% 2.1%	-1.50 [-5.74, 2.74] -1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Subtotal (95% CI) Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 1.4.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 1.4.3 asnloei 2019 Sige 2020 Viri 2019 Parekh 2018 Sharma 2021 Sistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	2; Ch 1.75 5.5 5.9 5.3 18 9.5	i ² = 19 (P = 0. 22 4.1 11.7 16.7 8.9	886 .46, df .08) 63 29 20 48 11	= 6 (P = 9 6.7 23 49.3 23	52 52 4.9 14 6.6	863); I ² = 6 63 28 15 24	47.7% 9% 0.9% 9.1% 2.1%	-1.89 [-4.00, 0.22] -1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Heterogeneity: Tau ² = 4.72 Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 Hasanloei 2019 Miri 2019 Viri 2019 Parekh 2018 Sharma 2021 Sistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	2; Ch 1.75 8 5.5 5.9 5.3 18 9.5	i ² = 19 (P = 0.) 22 4.1 11.7 16.7 8.9	.46, df .08) 63 29 20 48 11	9 6.7 23 49.3 23	52 52 4.9 14 6.6	63 28 15 24	0.9% 0.9% 9.1% 2.1%	-1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Fest for overall effect: Z = 1 1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 Han 2016 Hasanloei 2019 Nagels 2020 Viiri 2019 Viaguib 2020 Parekh 2018 Sharma 2021 Sistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	1.75 8 5.5 5.9 5.3 18 9.5	(P = 0 22 4.1 11.7 16.7 8.9	.08) 63 29 20 48 11	9 6.7 23 49.3 23	52 4.9 14 6.6	63 28 15 24	0.9% 9.1% 2.1%	-1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
1.2.2 100 MV% Bhattacharyya 2021 Ding 2017 Han 2016 Han 2016 Yasanloei 2019 Jingels 2020 Wiri 2019 Vaguib 2020 Parekh 2018 Sharma 2021 Sistanizad 2021 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	8 5.5 5.9 5.3 18 9.5	22 4.1 11.7 16.7 8.9	63 29 20 48 11	9 6.7 23 49.3 23	52 4.9 14 6.6	63 28 15 24	0.9% 9.1% 2.1%	-1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Bhattacharyya 2021 Ding 2017 9 Han 2016 19 Hasanloei 2019 33 ngels 2020 9 Viri 2019 19 Naguib 2020 20 Parekh 2018 5 Sharma 2021 10 Subtotal (95% CI) 1 Heterogeneity: Tau ² = 5.97 7 Fest for overall effect: Z = 3 3	8 5.5 5.9 5.3 18 9.5	22 4.1 11.7 16.7 8.9	63 29 20 48 11	9 6.7 23 49.3 23	52 4.9 14 6.6	63 28 15 24	0.9% 9.1% 2.1%	-1.00 [-14.94, 12.94] -1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Ding 2017 4 Han 2016 11 Hasanloei 2019 33 ngels 2020 33 Wiri 2019 19 Naguib 2020 2 Parekh 2018 33 Sharma 2021 6 Sistanizad 2021 11 Subtotal (95% CI) 14 Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	5.5 5.9 5.3 18 9.5	4.1 11.7 16.7 8.9	29 20 48 11	6.7 23 49.3 23	4.9 14 6.6	28 15 24	9.1% 2.1%	-1.20 [-3.55, 1.15] -7.10 [-15.85, 1.65]	
Han 2016 1 Hasanloei 2019 3 ngels 2020 3 Wiri 2019 1 Naguib 2020 2 Parekh 2018 3 Sharma 2021 6 Sistanizad 2021 1 Subtotal (95% CI) 1 Heterogeneity: Tau² = 5.97 7 Fest for overall effect: Z = 3 3	5.9 5.3 18 9.5	11.7 16.7 8.9	20 48 11	23 49.3 23	14 6.6	15 24	2.1%	-7.10 [-15.85, 1.65]	
Hasanloei 2019 34 ngels 2020 19 Viiri 2019 19 Parekh 2018 19 Sharma 2021 10 Sistanizad 2021 14 Subtotal (95% CI) 14 Heterogeneity: Tau ² = 5.97 7 Fest for overall effect: Z = 3 14	5.3 18 9.5	16.7 8.9	48 11	49.3	6.6	24	4 00/	44 00 5 40 44 0 501	
ngels 2020 Viri 2019 19 Naguib 2020 2 Parekh 2018 5 Sharma 2021 10 Sistanizad 2021 11 Subtotal (95% CI) 1 Heterogeneity: Tau ² = 5.97 5.97 Fest for overall effect: Z = 3 3	18 9.5	8.9	11	23			4.2%	-14.00 [-19.41, -8.59]	
Viri 2019 19 Naguib 2020 2 Parekh 2018 2 Sharma 2021 0 Sistanizad 2021 10 Subtotal (95% CI) 1 Heterogeneity: Tau ² = 5.97 5.97 Fest for overall effect: Z = 3 3	9.5	100		20	12.1	13	2.2%	-5.00 [-13.42, 3.42]	
Naguib 2020 2 Parekh 2018 3 Sharma 2021 0 Sistanizad 2021 11 Subtotal (95% CI) 1 Heterogeneity: Tau ² = 5.97 5.97 Fest for overall effect: Z = 3 3		12.2	22	28.7	23.6	18	1.2%	-9.20 [-21.24, 2.84]	
Parekh 2018 Sharma 2021 (1) Sistanizad 2021 11 Subtotal (95% CI) Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	2.3	1.1	45	3.2	2.2	41	12.0%	-0.90 [-1.65, -0.15]	*
Sharma 2021 (Sistanizad 2021 11 Subtotal (95% CI) Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	13	8.9	33	13	7.4	35	6.2%	0.00 [-3.90, 3.90]	
Sistanizad 2021 11 Subtotal (95% CI) Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	6.2	2.3	20	9.1	3	15	10.2%	-2.90 [-4.72, -1.08]	-
Subtotal (95% CI) Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3	8.3	8.4	16	25.4	6.6	14	4.3%	-7.10 [-12.48, -1.72]	
Heterogeneity: Tau ² = 5.97 Fest for overall effect: Z = 3			307			266	52.3%	-3.69 [-5.86, -1.51]	•
Fest for overall effect: Z = 3	'; Ch	i² = 33.	.86, df	= 9 (P <	< 0.000	1); I ² = 1	73%		
	3.32	(P = 0.	.0009)						
Fotal (95% CI)			1193			1129	100.0%	-2.66 [-4.04, -1.29]	•
Heterogeneity: Tau ² = 3.95	; Ch	i² = 53.	.57, df	= 16 (P	< 0.000	001); l²	= 70%	×	-20 -10 0 10 20
Test for overall effect: Z = 3	3.80	(P = 0.	.0001)						Favours [Vitamin D] Favours [Control]
Test for subaroup differenc	ces:	Chi² = 1	1.35. d	f = 1 (P	= 0.24). $I^2 = 20$	6.0%		
E 4									
t plots of the effects of v									

results showed no significant difference between the groups (n = 1,174; MD = -0.48; 95% CI, -2.37 to 1.40; *l*² = 31%; *p* = 0.61) (Figure 5) (14, 26–28, 31, 32, 35–37).

Similarly, all the subsequent subgroup analyses based on MV% suggested that vitamin D supplementation was associated with a significantly shorter length of stay in ICU (MD = -3.32 days; 95% CI, -5.40 to -1.25; p = 0.002) and hospital (MD = -1.42 days; 95% CI, -2.69 to -0.15; p = 0.03) in the MV subgroup rather than in the partly MV subgroup (Figures 4, 5).

Discussion

This systematic review and meta-analysis suggested that vitamin D significantly reduced short-term mortality, duration of MV, and ICU LOS in ICU patients. In addition, patients with MV may benefit more from vitamin D administration.

Possible explanations of the results of our research

Some mechanisms may explain our results. Vitamin D has been demonstrated to regulate skeletal muscle function through its active form, 1,25(OH)D, which is involved in muscle production, cell proliferation, differentiation, and regulation of protein synthesis (43). In animal studies, Foong et al. suggested that VDD causes airway hyperresponsiveness and increases airway smooth muscle mass in mice (44). Another study found that circulating 25(OH)D levels of 20 ng/mL caused smaller diaphragm muscle fiber diameter and a decreased ability to generate inspiratory force (45).

Compared with the adequate evidence that normal individuals benefit from vitamin D for skeletal muscle, the evidence in critically ill patients is limited. Some studies suggest that severe VDD is correlated with the severity of COPD (46). In one RCT focusing on ventilated patients, the authors found that high-dose vitamin D supplementation significantly increased hemoglobin (Pgroup*time = 0.01) and improved iron metabolism (47). The authors suggested that vitamin D increases haemoglobin concentration in critically ill adults by modulating iron modulators (47). Previous study has shown anemia is independently associated with extubation failure (48). Red blood cell transfusion in patients with severe COPD leads to a significant reduction of both the minute ventilation and work of breathing (49) and was more able to successfully wean these patients from mechanical ventilation (50). Yousefian et al. (40) showed that patients with vitamin D deficiency or insufficiency had more difficulty getting off the ventilator than patients with normal vitamin levels. Also, vitamin D supplementation significantly reduced the duration of MV in critically ill patients and, to some extent, reduced the occurrence of ventilatorrelated lung injury (12, 51, 52). In addition, several studies reported that VDD could cause muscle fiber atrophy and sarcopenia (53, 54).

Our results in relation to previous reviews

Our results contradict the findings of the two most recent metaanalyses (16, 18). The authors reported that supplemental vitamin D did not significantly reduce the mortality of ICU patients compared

Study or Subaroup	Events	Total	Events	Total	Weight	M-H Random 95% Cl	M-H Random 95% Cl
1.1.1 Partly MV							
Amrein 2011	6	12	6	13	3.9%	1 08 [0 48 2 45]	
Amrein 2014	67	237	84	238	21.1%	0.80 [0.61, 1.04]	
Ginde 2019	125	531	109	528	24.6%	1.14 [0.91, 1.43]	
Karsy 2019	11	134	13	133	4.3%	0.84 [0.39, 1.81]	
eaf 2014	8	36	7	31	3.3%	0.98 [0.40, 2.40]	
Quraishi 2015	5	20	3	10	1.8%	0.83 [0.25, 2.80]	
Wang 2024	15	41	7	20	4.8%	1.05 [0.51, 2.15]	
Subtotal (95% CI)		1011		973	63.8%	0.98 [0.84, 1.15]	◆
Total events	237		229				
Heterogeneity: Tau ² =	0.00: Chi ²	= 4.24	df = 6 (P	= 0.64	(); $ ^2 = 0\%$		
Test for overall effect: 2	Z = 0.25 (I	P = 0.8	D)		,,		
			1650				
1.1.2 100% MV							
Bhattacharyya 2021	23	63	30	63	11.9%	0.77 [0.51, 1.16]	
Ding 2017	3	29	5	28	1.5%	0.58 [0.15, 2.20]	· · · · · · · · · · · · · · · · · · ·
Han 2016	5	20	2	10	1.3%	1.25 [0.29, 5.35]	
Hasanloei 2019	3	48	5	24	1.5%	0.30 [0.08, 1.15]	· · · · ·
Ingels 2020	2	11	2	13	0.9%	1.18 [0.20, 7.06]	
Miri 2019	8	22	11	18	5.6%	0.60 [0.31, 1.16]	
Viroliaee 2017	5	24	11	22	3.3%	0.42 [0.17, 1.01]	
Naguib 2020	2	45	4	41	1.0%	0.46 [0.09, 2.36]	
Parekh 2018	2	33	2	35	0.8%	1.06 [0.16, 7.10]	
Sharma 2021	2	20	3	15	1.0%	0.50 [0.10, 2.63]	· · · · ·
Sistanizad 2021	5	16	12	14	4.4%	0.36 [0.17, 0.78]	
Yousefian 2019	8	33	6	33	3.0%	1.33 [0.52, 3.42]	
Subtotal (95% CI)		364		316	36.2%	0.65 [0.50, 0.84]	•
Fotal events	68		93				
Heterogeneity: Tau ² =	0.00; Chi ²	= 9.15	df = 11 (P = 0.6	61); l² = 0%	6	
Test for overall effect: 2	Z = 3.33 (I	P = 0.00	009)				
		1275		1200	100.0%	0.02 [0.70.0.00]	▲
Total (95% CI)	005	13/5	000	1289	100.0%	0.83 [0.70, 0.98]	•
	305	- 00 7	322	(D - 0	001-12 - 11	20/	
Heterogeneity: 1 au ² = 1	0.02; Chi ²	= 20.73	s, at = 18	(P = 0	.29); 1* = 13	5%	0.1 0.2 0.5 1 2 5 10
Test for overall effect:	z = 2.14 (I	= 0.03		/D - 0	007) 12 - 1	06 40/	Favours [Vitamin D] Favours [Control]
est for subaroub diffe	rences: C	$n_{r} = 7.3$	30. at = 1	P = 0	$.007$). $I^{-} = 8$	30.4%	

ventilation. 100 MV% = all patients received mechanical ventilation.

with controls. However, the lack of adequate published literature inclusion (18), the selection of only high-dose vitamin D RCTs (16), and the deficiency of exploration of heterogeneity sources (16, 18) might contribute to the unexplained bias and heterogeneity among their included trials. Moreover, at least 44 and 47% of patients without MV were included in their mortality results, respectively. In contrast, our results are consistent with another new meta-analysis by Menger et al. (n = 16 RCTs) (17). And yet, the authors conducted a subgroup analysis based on the route of vitamin D administration and found IV/ IM vitamin D (RR 0.59, 95% CI, 0.42-0.82) significantly reduced overall mortality compared with enteral/oral administration (RR 0.90, 95% CI, 0.71-1.15) (17). Thus, they believed IV/IM administration might have a more significant impact on mortality. Notably, the proportion of patients with MV was less than 50% in the enteral/oral subgroup, compared with 95% in the IV/IM subgroup. Thus, the greater effects on mortality reported by Menger et al. were more likely due to the more ventilated patients in the IM/IV group (95% vs. 50%) rather than the reduced mortality with IV/IM administration. In addition, compared with other RCTs in our meta-analysis, the VIOLET study (15), a recent large RCT, reported that early administration of high-dose enteral vitamin D did not significantly reduce the 90-day mortality or other clinical outcomes among critically ill. Similarly, only 33% of included patients received MV in that study.

To address these shortcomings, we performed a comprehensive search that included 19 RCTs of 2,754 patients, giving us more statistical power to examine our primary outcome. We further identified the heterogeneity by meta-regression analyses. Subgroup analysis based on MV% resolved the statistical heterogeneity among the included trials. Finally, all secondary outcomes showed that a subgroup of patients with MV could benefit more from vitamin D, lending credence from clinical practice to the robustness of our main result. In agreement, the aforementioned recent meta-analyses (16–18) consistently reported that the use of vitamin D significantly reduced the duration of MV, an outcome only for ventilated patients. This, yet again, validates our findings.

Discussion of the literature included

Although our meta-regression analysis suggested that only MV% was the primary source of heterogeneity, several potential influences are still worth discussing, such as the route of administration, dose, and baseline vitamin D status when vitamin D supplements are administered. Theoretically, IM/IV vitamin D application may be more appropriate

than enteral administration for critically ill patients for the commonly seen intestinal dysfunction in this patient population (55). Thus, patients are more likely to achieve serum 25(OH)D concentrations via IM/IV application than enteral administration. Surprisingly, our studies found that vitamin D via enteral/oral resulted in more significant increases in serum 25(OH)D concentrations than IV/IM (18 ng/mL vs. 4.1 ng/mL) than via IM/IV. This might be associated with the fact that most of these enteral/oral patients (78%) received high-dose vitamin D (≥500,000 IU), while all the IM/IV patients used vitamin D of not more than 300,000 IU. In addition, two included RCTs showed adequate gastrointestinal absorption by the enteral active form of vitamin D (32, 35). Leaf et al. found significantly increased plasma 1,25(OH)D levels in calcitriol-versus placebo-treated patients (75.7 vs. 16.9 pg./mL; *p* < 0.001) (32), whereas Naguib et al. reported that the enteral alfacalcidol change in serum 25 (OH)D was -9.2% (32.7%) in the control group, compared to 25.1% (36%) in the intervention group (35). Thus, our findings support enteral vitamin D with the current dose for critically ill patients. Considering that most serum 25(OH)D concentrations come from different studies, more data in the future are needed to confirm our findings.

The dosing regimen of vitamin D varied among the included trials, with more than 90% of patients receiving 300,000 IU or above. A recent meta-analysis has reported that high-dose vitamin D (\geq 300,000 IU) application could not significantly reduce mortality in critically ill patients (35). Our findings revealed that giving high-dose vitamin D does result in higher 25(OH)D concentrations (18.96 vs. 9.96 ng/mL). However, such high 25(OH)D concentrations did not translate into an improvement in mortality compared to low concentrations (RR 0.59, 95% CI, 0.94–0.80, vs. RR 0.57, 95% CI, 0.41–0.80). This finding appears to be explained in part by the difference in the MV% between the two groups, i.e., about 50% of patients with high 25(OH)D concentrations received MV compared to the low 25(OH)D group, in whom 95% of patients received MV. Thus, pursuing higher doses of vitamin D than currently available is unnecessary in future studies.

In the current study, we used <30 ng/mL vs. <20 ng/mL vs. no threshold limit for the subgroup by referring to other studies (17). So, our results do not clarify the efficacy evaluation of patients with severe VDD (<10 ng/mL). It is noteworthy that the two included large RCTs came to different conclusions regarding vitamin D supplementation in a subgroup of people with severe VDD (defined as \leq 12 ng/mL) (14, 15). The authors of the VITdAL-ICU trial observed lower in-hospital mortality in these patients (p = 0.04) (14), whereas Ginde et al. did not find a difference in mortality in their VIOLET trial (15). These opposite results might relate to the fact that the VITdAL-ICU trial used a loading dose of vitamin D followed by a maintenance dose, while the VIOLET trial did not. Again, we observed that the VITdAL-ICU trial (14) had a higher proportion of ventilated patients than the Ginde et al. study (15) (64% vs. 33%). Fortunately, the ongoing multinational, multicenter VITDALIZE trial (56) evaluating the efficacy of high doses of vitamin D (loading a dose of 540,000 IU, followed by 4,000 IU daily for 90 days) in patients with severe VDD (≤ 12 ng/mL) will provide hope for exploring this critical issue.

Study limitation

Firstly, most of the RCTs included in the current meta-analysis had a sample size of fewer than 200 patients, which may overestimate

the effect of our findings. Second, despite our meta-regression as well as subgroup analyses, there was still significant heterogeneity. Specially, variations in several definitions of vitamin D regimens, such as supplemental timing, frequency, and maintenance dose, as well as differences in treatment techniques, including sun exposure, age, adiposity, and gut function might cause heterogeneity and further compromise the robustness of our results (52, 57). Thirdly, the current meta-analysis only evaluated a single nutrient supplementation without considering the impact of other nutritional support treatments, including nutritional risk, energy and protein regimen, feeding intolerance, etc. Finally, we only assessed several clinically controversial factors for heterogeneity sources and may have missed some potential influences that need to be explored in future research.

Conclusion

In this updated meta-analysis, we demonstrate that vitamin D supplementation increased plasma 25(OH)D levels and significantly improved short-term mortality in critically ill patients with MV. In addition, ICU LOS and duration of MV were significantly reduced in this patient population. More well-designed RCTs are needed to validate our conclusions.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

W-HZ: Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Writing – original draft. J-HS: Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Writing – original draft. D-XY: Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Visualization, Writing – original draft. H-BH: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations,

References

1. Song L. Calcium and bone metabolism indices. Adv Clin Chem. (2017) 82:1-46. doi: 10.1016/bs.acc.2017.06.005

2. Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimmun. (2017) 85:78–97. doi: 10.1016/j.jaut.2017.07.007

3. Han JE, Alvarez JA, Staitieh B, Tangpricha V, Hao L, Ziegler TR, et al. Oxidative stress in critically ill ventilated adults: effects of vitamin D(3) and associations with alveolar macrophage function. *Eur J Clin Nutr.* (2018) 72:744–51. doi: 10.1038/s41430-017-0047-0

4. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* (2011) 96:1911–30. doi: 10.1210/jc.2011-0385

5. Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* (2024) 109:1907–47. doi: 10.1210/clinem/dgae290

6. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary reference intakes for calcium and vitamin D. AC Ross, CL Taylor, AL Yaktine and ValleHB Del, editors. Washington (DC): National Academies Press (US); (2011).

7. EFSA Panel on Dietetic Products, Nutrition and Allergies. Dietary reference values for vitamin D. *EFSA J.* (2016) 14:e4547. doi: 10.2903/j.efsa.2016.4484

8. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, et al. IOF position statement: vitamin D recommendations for older adults. *Osteoporos Int.* (2010) 21:1151-4. doi: 10.1007/s00198-010-1285-3

9. American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society consensus statement on vitamin D for prevention of falls and their consequences. *J Am Geriatr Soc.* (2014) 62:147–52. doi: 10.1111/jgs.12631

10. Vassiliou AG, Jahaj E, Mastora Z, Stagaki E, Orfanos SE, Kotanidou A. Serum admission 25-Hydroxyvitamin D levels and outcomes in initially non-septic critically ill patients. *Shock (Augusta, GA)*. (2018) 50:511–8. doi: 10.1097/SHK.000000000001105

11. Gomes TL, Fernandes RC, Vieira LL, Schincaglia RM, Mota JF, Nóbrega MS, et al. Low vitamin D at ICU admission is associated with cancer, infections, acute respiratory insufficiency, and liver failure. *Nutrition*. (2019) 60:235–40. doi: 10.1016/j.nut.2018.10.018

12. Putzu A, Belletti A, Cassina T, Clivio S, Monti G, Zangrillo A, et al. Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials. *J Crit Care*. (2017) 38:109–14. doi: 10.1016/j.jcrc.2016.10.029

13. Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. *Clin Nutr.* (2019) 38:48–79. doi: 10.1016/j.clnu.2018.08.037

14. Amrein K, Schnedl C, Holl A, Riedl R, Christopher KB, Pachler C, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. *JAMA*. (2014) 312:1520–30. doi: 10.1001/jama.2014.13204

15. Ginde AA, Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom CK, et al. Early high-dose vitamin D(3) for critically ill, vitamin D-deficient patients. *N Engl J Med.* (2019) 381:2529–40. doi: 10.1056/NEJMoa1911124

16. Gao Z, Xie J, Li C, Liu L, Yang Y. High dose vitamin D3 supplementation is not associated with lower mortality in critically ill patients: a meta-analysis of randomized control trials. *Front Nutr.* (2022) 9:762316. doi: 10.3389/fnut.2022.762316

17. Menger J, Lee ZY, Notz Q, Wallqvist J, Hasan MS, Elke G, et al. Administration of vitamin D and its metabolites in critically ill adult patients: an updated systematic review with meta-analysis of randomized controlled trials. *Crit Care*. (2022) 26:268. doi: 10.1186/s13054-022-04139-1

18. Singh S, Sarkar S, Gupta K, Rout A. Vitamin D supplementation in critically ill patients: a meta-analysis of randomized controlled trials. *Cureus*. (2022) 14:e24625. doi: 10.7759/cureus.24625

or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2025.1505616/ full#supplementary-material

19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg.* (2010) 8:336–41. doi: 10.1016/j.ijsu.2010.02.007

20. Wang F, Wu Y, Bo L, Lou J, Zhu J, Chen F, et al. The timing of tracheotomy in critically ill patients undergoing mechanical ventilation: a systematic review and metaanalysis of randomized controlled trials. *Chest.* (2011) 140:1456–65. doi: 10.1378/chest.11-2024

21. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928

22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* (2014) 14:135. doi: 10.1186/1471-2288-14-135

23. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol*. (2005) 5:13. doi: 10.1186/1471-2288-5-13

24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557

25. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. *J Clin Epidemiol.* (2008) 61:763–9. doi: 10.1016/j.jclinepi.2007.10.007

26. Amrein K, Sourij H, Wagner G, Holl A, Pieber TR, Smolle KH, et al. Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study. *Crit Care*. (2011) 15:R104. doi: 10.1186/cc10120

27. Bhattacharyya A, Subramaniam R, Baidya DK, Aggarwal P, Wig N. Effect of early Administration of Vitamin D on clinical outcome in critically ill Sepsis patients: a randomized placebo-controlled trial. *Indian J Crit Care Med.* (2021) 25:1147–54. doi: 10.5005/jp-journals-10071-23993

28. Han JE, Jones JL, Tangpricha V, Brown MA, Brown LAS, Hao L, et al. High dose vitamin D administration in ventilated intensive care unit patients: a pilot double blind randomized controlled trial. *J Clin Transl Endocrinol.* (2016) 4:59–65. doi: 10.1016/j.jcte.2016.04.004

29. Hasanloei MAV, Rahimlou M, Eivazloo A, Sane S, Ayremlou P, Hashemi R. Effect of oral versus intramuscular vitamin D replacement on oxidative stress and outcomes in traumatic mechanical ventilated patients admitted to intensive care unit. *Nutr Clin Pract.* (2020) 35:548–58. doi: 10.1002/ncp.10404

30. Ingels C, Vanhorebeek I, Van Cromphaut S, Wouters PJ, Derese I, Dehouwer A, et al. Effect of intravenous 25OHD supplementation on bone turnover and inflammation in prolonged critically ill patients. *Horm Metab Res.* (2020) 52:168–78. doi: 10.1055/a-1114-6072

31. Karsy M, Guan J, Eli I, Brock AA, Menacho ST, Park MS. The effect of supplementation of vitamin D in neurocritical care patients: RandomizEd clinical Trlal oF hYpovitaminosis D (RECTIFY). *J Neurosurg.* (2019) 133:1103–1112. doi: 10.3171/2018.11.JNS182713

32. Leaf DE, Raed A, Donnino MW, Ginde AA, Waikar SS. Randomized controlled trial of calcitriol in severe sepsis. *Am J Respir Crit Care Med.* (2014) 190:533–41. doi: 10.1164/rccm.201405-0988OC

33. Miri M, Kouchek M, Rahat Dahmardeh A, Sistanizad M. Effect of high-dose vitamin D on duration of mechanical ventilation in ICU patients. *Iran J Pharm Res.* (2019) 18:1067–72. doi: 10.22037/ijpr.2019.1100647

34. Miroliaee AE, Salamzadeh J, Shokouhi S, Fatemi A, Ardehali SH, Hajiesmaeili MR, et al. Effect of vitamin D supplementation on Procalcitonin as prognostic biomarker in patients with ventilator associated pneumonia complicated with vitamin D deficiency. *Iran J Pharm Res.* (2017) 16:1254–63.

35. Naguib SN, Sabry NA, Farid SF, Alansary AM. Short-term effects of Alfacalcidol on hospital length of stay in patients undergoing valve replacement surgery: a randomized clinical trial. *Clin Ther.* (2021) 43:e1–e18. doi: 10.1016/j. clinthera.2020.11.008

36. Parekh D, Dancer RCA, Scott A, D'Souza VK, Howells PA, Mahida RY, et al. Vitamin D to prevent lung injury following Esophagectomy-a randomized, placebo-controlled trial. *Crit Care Med.* (2018) 46:e1128–35. doi: 10.1097/CCM.00000000003405

37. Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M, Bajwa EK, et al. Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in Sepsis: a randomized, placebo-controlled trial. *Crit Care Med.* (2015) 43:1928–37. doi: 10.1097/CCM.00000000001148

38. Sharma S, Kumar A, Choudhary A, Sharma S, Khurana L, Sharma N, et al. Neuroprotective role of Oral vitamin D supplementation on consciousness and inflammatory biomarkers in determining severity outcome in acute traumatic brain injury patients: a double-blind randomized clinical trial. *Clin Drug Investig.* (2020) 40:327–34. doi: 10.1007/s40261-020-00896-5

39. Sistanizad M, Kouchek M, Miri M, Salarian S, Shojaei S, Vasegh FM, et al. High dose vitamin D improves total serum antioxidant capacity and ICU outcome in critically ill patients-a randomized, double-blind clinical trial. *Eur J Integr Med.* (2021) 42:101271. doi: 10.1016/j.eujim.2020.101271

40. Yousefian M, Sadegi S, Sakaki M. Vitamin D supplements' effect on expediting the weaning process in patients with the stroke. *Electron J Gen Med.* (2019) 16. doi: 10.29333/ejgm/94224

41. Ding F, Zang B, Fu J, Ji K. Effect of vitamin D(3) on the severity and prognosis of patients with sepsis: a prospective randomized double-blind placebo study. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. (2017) 29:106–10. doi: 10.3760/cma.j.issn.2095-4352.2017.02.003

42. Wang AY, Yeh YC, Cheng KH, Han YY, Chiu CT, Chang CC, et al. Efficacy and safety of enteral supplementation with high-dose vitamin D in critically ill patients with vitamin D deficiency. *J Formos Med Assoc.* (2024) S0929-6646:00241–9. doi: 10.1016/j.jfma.2024.05.005

43. Montenegro KR, Cruzat V, Carlessi R, Newsholme P. Mechanisms of vitamin D action in skeletal muscle. *Nutr Res Rev.* (2019) 32:192–204. doi: 10.1017/S0954422419000064

44. Foong RE, Shaw NC, Berry LJ, Hart PH, Gorman S, Zosky GR. Vitamin D deficiency causes airway hyperresponsiveness, increases airway smooth muscle mass, and reduces TGF- β expression in the lungs of female BALB/c mice. *Physiol Rep.* (2014) 2:e00276. doi: 10.1002/phy2.276

45. Ray AD, Personius KE, Williamson DL, Dungan CM, Dhillon SS, Hershberger PA. Vitamin D3 intake modulates diaphragm but not peripheral muscle force in young mice. *J Appl Physiol*. (2016) 120:1124–31. doi: 10.1152/japplphysiol.00643.2015

46. Zhu B, Zhu B, Xiao C, Zheng Z. Vitamin D deficiency is associated with the severity of COPD: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis.* (2015) 10:1907–16. doi: 10.2147/COPD.S89763

47. Smith EM, Jones JL, Han JE, Alvarez JA, Sloan JH, Konrad RJ, et al. High-dose vitamin D(3) administration is associated with increases in hemoglobin concentrations in mechanically ventilated critically ill adults: a pilot double-blind, randomized, placebocontrolled trial. *JPEN J Parenter Enteral Nutr.* (2018) 42:87–94. doi: 10.1177/ 0148607116678197

48. Khamiees M, Raju P, DeGirolamo A, Amoateng-Adjepong Y, Manthous CA. Predictors of extubation outcome in patients who have successfully completed a spontaneous breathing trial. *Chest.* (2001) 120:1262–70. doi: 10.1378/chest.120.4.1262

49. Schönhofer B, Wenzel M, Geibel M, Köhler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. *Crit Care Med.* (1998) 26:1824–8. doi: 10.1097/00003246-199811000-00022

50. Schönhofer B, Böhrer H, Köhler D. Blood transfusion facilitating difficult weaning from the ventilator. *Anaesthesia*. (1998) 53:181–4. doi: 10.1046/j.1365-2044.1998.00275.x

51. Parekh D, Thickett DR, Turner AM. Vitamin D deficiency and acute lung injury. *Inflamm Allergy Drug Targets*. (2013) 12:253–61. doi: 10.2174/1871528111 3129990049

52. Quraishi SA, Bhan I, Matthay MA, Thompson BT, Camargo CA Jr, Bajwa EK. Vitamin D status and clinical outcomes in acute respiratory distress syndrome: a secondary analysis from the assessment of low tidal volume and elevated end-expiratory volume to obviate lung injury (ALVEOLI) trial. *J Intensive Care Med.* (2022) 37:793–802. doi: 10.1177/08850666211028139

53. Mizuno T, Hosoyama T, Tomida M, Yamamoto Y, Nakamichi Y, Kato S, et al. Influence of vitamin D on sarcopenia pathophysiology: a longitudinal study in humans and basic research in knockout mice. *J Cachexia Sarcopenia Muscle*. (2022) 13:2961–73. doi: 10.1002/jcsm.13102

54. Garcia M, Seelaender M, Sotiropoulos A, Coletti D, Lancha AH Jr. Vitamin D, muscle recovery, sarcopenia, cachexia, and muscle atrophy. *Nutrition*. (2019) 60:66–9. doi: 10.1016/j.nut.2018.09.031

55. Blaser AR, Starkopf J, Kirsimägi Ü, Deane AM. Definition, prevalence, and outcome of feeding intolerance in intensive care: a systematic review and meta-analysis. *Acta Anaesthesiol Scand.* (2014) 58:914–22. doi: 10.1111/aas.12302

56. Amrein K, Parekh D, Westphal S, Preiser JC, Berghold A, Riedl R, et al. Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study). *BMJ Open.* (2019) 9:e031083. doi: 10.1136/bmjopen-2019-031083

57. Thacher TD, Clarke BL. Vitamin D insufficiency. *Mayo Clin Proc.* (2011) 86:50–60. doi: 10.4065/mcp.2010.0567